{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:50:35Z","timestamp":1793260235376,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["CMRPG3N1031"],"award-info":[{"award-number":["CMRPG3N1031"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["CMRPG3N1032"],"award-info":[{"award-number":["CMRPG3N1032"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The direct oral anticoagulant (DOAC) score was recently developed to predict bleeding risk in patients with atrial fibrillation (AF) receiving oral anticoagulants. However, limited data show inconsistent results comparing its performance to the conventional HAS-BLED score in Asian populations with non-valvular AF receiving DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We enrolled 21 142 patients with non-valvular AF receiving DOACs from a multicentre database in Taiwan (June 2012\u2013December 2021). The primary endpoint was major bleeding events. Major bleeding events were defined according to the ISTH criteria. Areas under receiver operating characteristic curves (AUCs) were calculated for each score, with differences assessed using DeLong test. A total of 21 142 AF patients (mean age 75.9 \u00b1 11.0 years; 41% female) treated with DOAC were included in the analysis. Major bleeding events occurred in 681 patients in 1-year follow-up (3.66%\/year). There were 82(0.43%\/year) intracranial haemorrhage event occurred. Both the DOAC and HAS-BLED scores are associated with a significant risk of major bleeding event, with only modest predictive performance (AUC &amp;lt; 0.7). The DOAC score showed a slightly but statistically significantly higher AUC compared with the HAS-BLED score [AUC: 0.670 (95% CI: 0.650\u20130.689) vs. 0.642 (0.623\u20130.663); P &amp;lt; 0.001]. Results from several reclassification analyses favoured the DOAC score. Both the two scores showed a good calibration for the low to intermediate risk categories, while the two bleeding risk scores both overestimate the risk of major bleeding risk for the high risk categories. Subgroup analyses indicated that the superiority of DOAC score over HAS-BLED score is primarily driven by elderly patients (\u226575 years) and prediction in risk of gastrointestinal bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The DOAC score, which employs a more granular scoring system compared to the HAS-BLED score, may enable finer bleeding risk discrimination among Asian patients with non-valvular AF receiving DOAC therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euaf251","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:51:53Z","timestamp":1759492313000},"source":"Crossref","is-referenced-by-count":9,"title":["Performance of DOAC and HAS-BLED scores in predicting major bleeding in Asian patients with non-valvular atrial fibrillation receiving direct oral anticoagulants"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-8503","authenticated-orcid":false,"given":"Yi-Hsin","family":"Chan","sequence":"first","affiliation":[{"name":"The Cardiovascular Department, Chang Gung Memorial Hospital , Linkou, Taoyuan ,","place":["Taiwan"]},{"name":"College of Medicine, Chang Gung University , Taoyuan ,","place":["Taiwan"]},{"name":"School of Traditional Chinese Medicine, College of Medicine, Chang-Gung University , Taoyuan City ,","place":["Taiwan"]},{"name":"Microscopy Core Laboratory, Chang Gung Memorial Hospital , Linkou, Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7891-9514","authenticated-orcid":false,"given":"Yi-Wei","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Applied Statistics and Information Science, Ming Chuan University , Taoyuan City ,","place":["Taiwan"]},{"name":"Artificial Intelligence Development Center, Fu Jen Catholic University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-1295","authenticated-orcid":false,"given":"Shao-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Linkou Medical Center, Chang Gung Memorial Hospital, Chang Gung University , Taoyuan City ,","place":["Taiwan"]},{"name":"Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital , Taoyuan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6587-3094","authenticated-orcid":false,"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital , No. 201, Sec. 2, Shih-Pai Road, 112062,Taipei ,","place":["Taiwan"]},{"name":"Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University , 11221, Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2025103116334974500_euaf251-B1","doi-asserted-by":"crossref","first-page":"euae195","DOI":"10.1093\/europace\/euae195","article-title":"Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021","volume":"26","author":"Cheng","year":"2024","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B2","doi-asserted-by":"crossref","first-page":"euae298","DOI":"10.1093\/europace\/euae298","article-title":"Spotlight on the 2024 ESC\/EACTS management of atrial fibrillation guidelines: 10 novel key aspects","volume":"26","author":"Rienstra","year":"2024","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia Pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"2025103116334974500_euaf251-B4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025103116334974500_euaf251-B5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2025103116334974500_euaf251-B6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/joa3.12652","article-title":"2021 focused update of the 2017 consensus guidelines of the Asia Pacific heart rhythm society (APHRS) on stroke prevention in atrial fibrillation","volume":"37","author":"Chao","year":"2021","journal-title":"J Arrhythm"},{"key":"2025103116334974500_euaf251-B7","doi-asserted-by":"crossref","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal","volume":"25","author":"Lip","year":"2023","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejim.2022.10.021","article-title":"Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: insights from the ARISTOPHANES study","volume":"108","author":"Deitelzweig","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025103116334974500_euaf251-B9","doi-asserted-by":"crossref","first-page":"euae183","DOI":"10.1093\/europace\/euae183","article-title":"Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS","volume":"26","author":"Kirchhof","year":"2024","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B10","doi-asserted-by":"crossref","first-page":"euad120","DOI":"10.1093\/europace\/euad120","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study","volume":"25","author":"Liu","year":"2023","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2025103116334974500_euaf251-B12","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"2025103116334974500_euaf251-B13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation)","volume":"58","author":"Fang","year":"2011","journal-title":"Study. J Am Coll Cardiol"},{"key":"2025103116334974500_euaf251-B14","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"2025103116334974500_euaf251-B15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ehjqcco\/qcab069","article-title":"Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry","volume":"8","author":"Proietti","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025103116334974500_euaf251-B16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/europace\/euab303","article-title":"Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis","volume":"24","author":"Grymonprez","year":"2022","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"2025103116334974500_euaf251-B18","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/bcp.16396","article-title":"Assessing the applicability of the DOAC, HAS-BLED and ORBIT risk scores in Chinese patients on non-vitamin K antagonist oral anticoagulants","volume":"91","author":"Fan","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2025103116334974500_euaf251-B19","doi-asserted-by":"crossref","first-page":"e036417","DOI":"10.1161\/JAHA.124.036417","article-title":"Association between direct oral anticoagulant score and bleeding events in patients with atrial fibrillation following transcatheter aortic valve replacement: a retrospective multicenter cohort study","volume":"13","author":"Harano","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025103116334974500_euaf251-B20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bj.2021.12.006","article-title":"Discharge status validation of the Chang Gung Research database in Taiwan","volume":"45","author":"Huang","year":"2022","journal-title":"Biomed J"},{"key":"2025103116334974500_euaf251-B21","doi-asserted-by":"crossref","first-page":"e009263","DOI":"10.1161\/JAHA.118.009263","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with impaired liver function: a retrospective cohort study","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025103116334974500_euaf251-B22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang gung research database: a multi-institutional database consisting of original medical records","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed J"},{"key":"2025103116334974500_euaf251-B23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11239-018-1792-1","article-title":"Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia","volume":"47","author":"Wang","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2025103116334974500_euaf251-B24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2025103116334974500_euaf251-B25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry","volume":"128","author":"Mei","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025103116334974500_euaf251-B26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2025103116334974500_euaf251-B27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2025103116334974500_euaf251-B28","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur Heart J"},{"key":"2025103116334974500_euaf251-B29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1472-6947-8-53","article-title":"Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers","volume":"8","author":"Vickers","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"key":"2025103116334974500_euaf251-B30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hrthm.2016.12.036","article-title":"Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants","volume":"14","author":"Park","year":"2017","journal-title":"Heart Rhythm"},{"key":"2025103116334974500_euaf251-B31","doi-asserted-by":"crossref","first-page":"132018","DOI":"10.1016\/j.ijcard.2024.132018","article-title":"Relative performance evaluation of four bleeding risk scores in atrial fibrillation patients. What does the new DOAC score provide?","volume":"407","author":"Abu-Assi","year":"2024","journal-title":"Int J Cardiol"},{"key":"2025103116334974500_euaf251-B32","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"2025103116334974500_euaf251-B33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"2025103116334974500_euaf251-B34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE)","volume":"168","author":"Goto","year":"2014","journal-title":"Trial. Am Heart J"},{"key":"2025103116334974500_euaf251-B35","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","article-title":"Edoxaban vs. Warfarin in East Asian patients with atrial fibrillation- an ENGAGE AF-TIMI 48 subanalysis","volume":"80","author":"Yamashita","year":"2016","journal-title":"Circ J"},{"key":"2025103116334974500_euaf251-B36","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025103116334974500_euaf251-B37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025103116334974500_euaf251-B38","doi-asserted-by":"crossref","first-page":"102039","DOI":"10.1016\/j.eclinm.2023.102039","article-title":"Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF registry","volume":"63","author":"Romiti","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025103116334974500_euaf251-B39","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2025103116334974500_euaf251-B40","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"key":"2025103116334974500_euaf251-B41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics15020588","article-title":"Is a lower dose of rivaroxaban required for Asians? A systematic review of a population pharmacokinetics and pharmacodynamics analysis of rivaroxaban","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025103116334974500_euaf251-B42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jacasi.2023.08.007","article-title":"Direct oral anticoagulant dosing in patients with atrial fibrillation: an Asian perspective","volume":"3","author":"Chao","year":"2023","journal-title":"JACC Asia"},{"key":"2025103116334974500_euaf251-B43","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1111\/bcp.15265","article-title":"Impact of P-glycoprotein and\/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis","volume":"88","author":"Grymonprez","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025103116334974500_euaf251-B44","first-page":"e007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025103116334974500_euaf251-B45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2025.04.038","article-title":"Chronic kidney disease classification according to different formulas and impact on adverse outcomes in patients with atrial fibrillation: a report from a prospective observational European registry","volume":"136","author":"Boriani","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2025103116334974500_euaf251-B46","doi-asserted-by":"crossref","first-page":"14423","DOI":"10.1038\/s41598-024-65237-4","article-title":"Observational study of frailty in older Japanese patients with non-valvular atrial fibrillation receiving anticoagulation therapy","volume":"14","author":"Matsui","year":"2024","journal-title":"Sci Rep"},{"key":"2025103116334974500_euaf251-B47","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/europace\/euac123","article-title":"EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"25","author":"Savelieva","year":"2023","journal-title":"Europace"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euaf251\/64488761\/euaf251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/11\/euaf251\/64488761\/euaf251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/11\/euaf251\/64488761\/euaf251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:34:01Z","timestamp":1761942841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euaf251\/8272884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaf251","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,3]]},"article-number":"euaf251"}}